CALC Form 4: New 68.6k Stock Options Issued to Director Robert Wilson
Rhea-AI Filing Summary
Form 4 highlights for CalciMedica, Inc. (CALC): Director Robert N. Wilson reported the award of four separate stock-option grants on 24 June 2025 following shareholder approval of the amended 2023 Equity Incentive Plan earlier that same day.
Key details: the grants total 68,593 options with exercise prices of $1.53 (three tranches) and $1.65 (one tranche). Vesting schedules differ: (i) 10,000 options vest monthly over 12 months from 26 Mar 2025; (ii) 12,031 options are immediately exercisable; (iii) 36,562 options vest monthly over 12 months from 1 Apr 2025; and (iv) 10,000 options vest monthly over 12 months from 24 Jun 2025 (or fully by the 2026 AGM). All grants expire in April 2035 (first three tranches) or June 2035 (last tranche) and are held directly by the director.
Implications for investors: These are incentive grants—not market purchases or sales—so they do not convey a valuation signal. They do, however, increase the company’s fully diluted share count by roughly 0.6 % (based on ~11 million shares outstanding as of the last 10-Q) and underline ongoing reliance on equity-based compensation. The low strike prices signal CALC’s current trading range and align the director’s upside with shareholders should the share price rise above $1.65 before the 2035 expiry.
Positive
- Alignment of interests: Options link director compensation directly to future share-price appreciation.
- Structured vesting: Monthly vesting over one year encourages continuous board engagement.
Negative
- Dilution risk: 68,593 additional options raise fully diluted share count (≈0.6 %).
- Low strike price: Grants priced near historic lows could be viewed as opportunistic if share price rebounds sharply.
Insights
TL;DR: Routine director option grant; minimal dilution, neutral governance impact.
The award follows shareholder approval of the amended equity plan, satisfying best-practice process. Total new options equal roughly 0.6 % of shares outstanding, well within typical small-cap dilution thresholds. Vesting schedules promote 12-month service alignment, and one tranche is immediately exercisable, allowing early ownership but not cashless benefit unless price rises. No red flags on grant size, pricing or disclosure. Overall, the filing is procedural rather than strategically significant.
TL;DR: Option grant modestly dilutes; no buy/sell signal, watch incentive alignment.
The director neither bought nor sold stock in the open market, so trading sentiment is unchanged. Strike prices ($1.53–$1.65) hover near recent trading lows, giving strong leverage if pipeline catalysts hit. For valuation models, add ~68.6k shares to the option overhang; impact on EPS is immaterial today but could grow if additional grants follow. Investors should focus on clinical progress rather than this administrative filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 12,031 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 36,562 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
Footnotes (1)
- The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025. Immediately exercisable. 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.
